Literature DB >> 16509800

Extracorporeal shockwave therapy for Peyronie's disease: who benefits?

Joby Taylor1, James A Forster, Anthony J Browning, C Shekhar Biyani.   

Abstract

BACKGROUND AND
PURPOSE: Extracorporeal shockwave therapy (ESWT) has been reported to improve the symptoms of Peyronie's disease. However, the response rates to this treatment appear to be variable. This study aimed to determine whether any patient or plaque characteristics are associated with a better outcome. PATIENTS AND METHODS: A series of 36 patients with Peyronie's disease received ESWT as a primary treatment. Subjective response rates were compared on the basis of patient age, degree of pretreatment penile curvature, predisposing medical factors, duration of disease, and extent of plaque calcification.
RESULTS: Ten men (27.8%) reported subjective improvements in curvature after ESWT. Of the factors considered, only age and pretreatment curvature influenced outcomes: 50% of the men below the mean age reported improvement compared with 5.6% of older men and 62.5% of men with mild curvature reported improvement compared with 8.3% of those with severe curvature.
CONCLUSION: The response to EWST is not the same for all men with Peyronie's disease. Younger men and those with milder curvature have the best outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16509800     DOI: 10.1089/end.2006.20.135

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  2 in total

1.  Pro: does shockwave therapy have a place in the treatment of Peyronie's disease?

Authors:  Eric Chung
Journal:  Transl Androl Urol       Date:  2016-06

Review 2.  Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.

Authors:  Eric Chung
Journal:  Korean J Urol       Date:  2015-11-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.